All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
The FDA grants UCART123 Investigational New Drug approval for treatment of AML
Bookmark this article
This month, the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) status to UCART123 for the treatment of patients with Acute Myeloid Leukemia (AML).1
UCART123 is an allogenic gene-edited Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD123.1 CD123, the Interleukin 3 α-Chain Receptor (IL3RA), is differentially and significantly overexpressed in the majority of patients with AML. Additionally, CD123 has been identified as a marker for Leukemic Stem Cells (LSCs),2 which are a small population of stem cells that have properties including differentiation, self-renewal, and homeostatic control, and they contribute to the maintenance and propagation of AML. In AML, the LSC reservoir can lead to disease resistance, relapse, and often death in patients.3
Currently, UCART123 is at the preclinical stage of development.4 The IND approval granted by the FDA allows UCART123 to be evaluated in phase I clinical trials in AML patients. Trials are anticipated to start in the first half of this year.1
- ASH Clinical News: FDA Grants IND Application for CAR T-Cell Therapy. 2017 Feb 27.http://www.ashclinicalnews.org/fda-grants-investigational-new-drug-approval-car-t-cell-therapy/ [Accessed 2017 Feb 27].
- Al-Hussaini M.et al. Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform. Blood. 2016 Jan 7: 127(1): 122–131. DOI: 1182/blood-2014-05-575704. Epub 2015 Nov 3.
- Pollyea D. A. et al. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica . 2014 Aug; 99(8): 1277–1284. DOI: 3324/haematol.2013.085209.
- Cellectis: Universal Chimeric Antigene Receptors. https://www.cellectis.com/en/content/ucarts [Accessed 2017 Feb 27].
More about...
Your opinion matters
28 votes - 49 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox